PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34706843-0 2022 Corrigendum to "TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/beta-catenin signaling pathway and promoting the epithelial mesenchymal transition" (2017 Aug 28;402:117-130). Cisplatin 33-42 catenin beta 1 Homo sapiens 104-116 34306338-0 2021 Effect of miR-133b on progression and cisplatin resistance of triple-negative breast cancer through FGFR1-Wnt-beta-catenin axis. Cisplatin 38-47 catenin beta 1 Homo sapiens 110-122 34457055-0 2021 Combination of nigericin with cisplatin enhances the inhibitory effect of cisplatin on epithelial ovarian cancer metastasis by inhibiting slug expression via the Wnt/beta-catenin signalling pathway. Cisplatin 30-39 catenin beta 1 Homo sapiens 166-178 34457055-0 2021 Combination of nigericin with cisplatin enhances the inhibitory effect of cisplatin on epithelial ovarian cancer metastasis by inhibiting slug expression via the Wnt/beta-catenin signalling pathway. Cisplatin 74-83 catenin beta 1 Homo sapiens 166-178 34457055-13 2021 Nigericin also enhanced the inhibitory effects of cisplatin on the expression levels of MMP7, as well as the inhibitory effects of cisplatin on the expression levels of beta-catenin and GSK-3beta, indicating that nigericin and cisplatin regulated in the Wnt/beta-catenin signalling pathway. Cisplatin 131-140 catenin beta 1 Homo sapiens 169-181 34457055-13 2021 Nigericin also enhanced the inhibitory effects of cisplatin on the expression levels of MMP7, as well as the inhibitory effects of cisplatin on the expression levels of beta-catenin and GSK-3beta, indicating that nigericin and cisplatin regulated in the Wnt/beta-catenin signalling pathway. Cisplatin 131-140 catenin beta 1 Homo sapiens 258-270 34457055-13 2021 Nigericin also enhanced the inhibitory effects of cisplatin on the expression levels of MMP7, as well as the inhibitory effects of cisplatin on the expression levels of beta-catenin and GSK-3beta, indicating that nigericin and cisplatin regulated in the Wnt/beta-catenin signalling pathway. Cisplatin 227-236 catenin beta 1 Homo sapiens 169-181 34457055-13 2021 Nigericin also enhanced the inhibitory effects of cisplatin on the expression levels of MMP7, as well as the inhibitory effects of cisplatin on the expression levels of beta-catenin and GSK-3beta, indicating that nigericin and cisplatin regulated in the Wnt/beta-catenin signalling pathway. Cisplatin 227-236 catenin beta 1 Homo sapiens 258-270 34097426-0 2021 Knockdown of USP9X reverses cisplatin resistance by decreasing beta-catenin expression in nasopharyngeal carcinoma cells. Cisplatin 28-37 catenin beta 1 Homo sapiens 63-75 34097426-6 2021 We found that USP9X and beta-catenin expressions in cisplatin-resistance cell lines (HNE1/DDP) were much higher than cisplatin-sensitive cell lines (HNE1) at both mRNA and protein levels. Cisplatin 52-61 catenin beta 1 Homo sapiens 24-36 34893064-0 2021 Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of beta-catenin. Cisplatin 62-66 catenin beta 1 Homo sapiens 153-165 34893064-22 2021 The NORAD/miR-224-3p/MTDH axis promoted CDDP resistance and progression in ESCC cells by promoting nuclear accumulation of beta-catenin in vitro and in vivo. Cisplatin 40-44 catenin beta 1 Homo sapiens 123-135 34289571-7 2021 Western blot was used to detect the expression of Wnt/beta-catenin signaling pathway related proteins.CCK-8 was used to detect the proliferation inhibition of cells treated with different concentrations of cisplatin after transfection. Cisplatin 206-215 catenin beta 1 Homo sapiens 54-66 35606602-13 2022 In conclusion, FAT1 knockdown might enhance the stemness and ABCC3-related cisplatin resistance of ESCC cells via Wnt/beta-catenin signaling pathway. Cisplatin 75-84 catenin beta 1 Homo sapiens 118-130 35332692-0 2022 Knockdown of circ_0055412 promotes cisplatin sensitivity of glioma cells through modulation of CAPG and Wnt/beta-catenin signaling pathway. Cisplatin 35-44 catenin beta 1 Homo sapiens 108-120 35332692-11 2022 CONCLUSION: Circ_0055412 contributed to cisplatin resistance of glioma cells via stabilizing CAPG mRNA and modulating Wnt/beta-catenin signaling pathway. Cisplatin 40-49 catenin beta 1 Homo sapiens 122-134 35609308-0 2022 Asiatic acid re-sensitizes multidrug-resistant A549/DDP cells to cisplatin by down regulating long non-coding RNA metastasis associated lung adenocarcinoma transcript 1/beta-catenin signaling. Cisplatin 65-74 catenin beta 1 Homo sapiens 169-181 35153759-0 2021 Magnesium-Assisted Cisplatin Inhibits Bladder Cancer Cell Survival by Modulating Wnt/beta-Catenin Signaling Pathway. Cisplatin 19-28 catenin beta 1 Homo sapiens 85-97 35587162-0 2022 Integrin-linked kinase affects the sensitivity of esophageal squamous cell carcinoma cells to chemotherapy with cisplatin via the Wnt/beta-catenin signaling pathway. Cisplatin 112-121 catenin beta 1 Homo sapiens 134-146 35217794-7 2022 METTL1 upregulated the WNT/beta-catenin signaling pathway and promoted NPC cell epithelial-mesenchymal transition (EMT) and chemoresistance to cisplatin and docetaxel in vitro and in vivo. Cisplatin 143-152 catenin beta 1 Homo sapiens 27-39 35153759-5 2021 Most importantly, a marked decrease in nuclear beta-catenin was observed in cells that received cisplatin treatment. Cisplatin 96-105 catenin beta 1 Homo sapiens 47-59 35153759-6 2021 In addition, the nuclear beta-catenin in cisplatin treated cells was further down-regulated by supplementing MgCl2. Cisplatin 41-50 catenin beta 1 Homo sapiens 25-37 35153759-11 2021 Our findings reveal that magnesium could contribute to cisplatin-based chemotherapy by moderately regulating the Wnt/beta-catenin signaling pathway. Cisplatin 55-64 catenin beta 1 Homo sapiens 117-129 34001990-0 2021 Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/beta-catenin and TGF-beta signaling. Cisplatin 0-9 catenin beta 1 Homo sapiens 133-145 33423190-0 2021 Reversal of cisplatin sensitization and abrogation of cisplatin-enriched cancer stem cells in 5-8F nasopharyngeal carcinoma cell line through a suppression of Wnt/beta-catenin-signaling pathway. Cisplatin 12-21 catenin beta 1 Homo sapiens 163-175 33923996-4 2021 It has previously been shown that Wnt/beta-catenin signaling is active in GCTs suggesting that its inhibitors LGK974 and PRI-724 may show promise in the management of cisplatin-refractory GCTs. Cisplatin 167-176 catenin beta 1 Homo sapiens 38-50 33923996-6 2021 Taking a genoproteomic approach and utilizing xenograft models we found the increased level of beta-catenin in 2 of 4 cisplatin-resistant (CisR) cell lines (TCam-2 CisR and NCCIT CisR) and the decreased level of beta-catenin and cyclin D1 in cisplatin-resistant NTERA-2 CisR cell line. Cisplatin 118-127 catenin beta 1 Homo sapiens 95-107 33923996-6 2021 Taking a genoproteomic approach and utilizing xenograft models we found the increased level of beta-catenin in 2 of 4 cisplatin-resistant (CisR) cell lines (TCam-2 CisR and NCCIT CisR) and the decreased level of beta-catenin and cyclin D1 in cisplatin-resistant NTERA-2 CisR cell line. Cisplatin 242-251 catenin beta 1 Homo sapiens 95-107 33923996-9 2021 Our data strongly suggests that a Wnt/beta-catenin signaling is altered in cisplatin-resistant GCT cell lines and the inhibition with PRI-724 is effective in NTERA-2 CisR cells. Cisplatin 75-84 catenin beta 1 Homo sapiens 38-50 33854371-0 2021 MicroRNA-32 and MicroRNA-548a Promote the Drug Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting ROBO1 and Inhibiting the Activation of Wnt/beta-Catenin Axis. Cisplatin 98-107 catenin beta 1 Homo sapiens 164-176 33423190-0 2021 Reversal of cisplatin sensitization and abrogation of cisplatin-enriched cancer stem cells in 5-8F nasopharyngeal carcinoma cell line through a suppression of Wnt/beta-catenin-signaling pathway. Cisplatin 54-63 catenin beta 1 Homo sapiens 163-175 33423190-7 2021 Furthermore, a tankyrase inhibitor for Wnt/beta-catenin pathway, XAV939, substantially reduced CSCs and retrieved the cisplatin sensitivity in 5-8F CDDP. Cisplatin 118-127 catenin beta 1 Homo sapiens 43-55 33423190-7 2021 Furthermore, a tankyrase inhibitor for Wnt/beta-catenin pathway, XAV939, substantially reduced CSCs and retrieved the cisplatin sensitivity in 5-8F CDDP. Cisplatin 148-152 catenin beta 1 Homo sapiens 43-55 33423190-10 2021 In conclusion, the enhancement of CSCs in 5-8F NPC cells caused by the instant cisplatin treatment is initially mediated through the upregulation of beta-catenin and activation of Wnt/beta-catenin signaling pathway. Cisplatin 79-88 catenin beta 1 Homo sapiens 149-161 33423190-10 2021 In conclusion, the enhancement of CSCs in 5-8F NPC cells caused by the instant cisplatin treatment is initially mediated through the upregulation of beta-catenin and activation of Wnt/beta-catenin signaling pathway. Cisplatin 79-88 catenin beta 1 Homo sapiens 184-196 33302041-6 2021 RESULTS: It was observed that following p38 inhibition, cisplatin resistant HNSCC cells exhibited significant reduction in expression of CSC markers, beta-catenin, reduced migration potential and sphere forming ability along with increased apoptotic index demonstrating there was increased sensitivity towards Cisplatin. Cisplatin 56-65 catenin beta 1 Homo sapiens 150-162 33680959-0 2021 Wilms" Tumor 1-Associated Protein Contributes to Chemo-Resistance to Cisplatin Through the Wnt/beta-Catenin Pathway in Endometrial Cancer. Cisplatin 69-78 catenin beta 1 Homo sapiens 95-107 33680959-13 2021 Conclusions: WTAP might promote the chemo-resistance of EC cells to cisplatin through activating the Wnt/beta-catenin pathway. Cisplatin 68-77 catenin beta 1 Homo sapiens 105-117 33738259-9 2021 Furthermore, Hsp90 enhanced the AKT/GSK3beta signaling, and AKT signaling played a critical role in Hsp90-induced accumulation and transcriptional activity of beta-catenin, as well as multi-drug resistance to paclitaxel and cisplatin. Cisplatin 224-233 catenin beta 1 Homo sapiens 159-171 33360300-0 2021 MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/beta-catenin in serous ovarian cancers. Cisplatin 62-71 catenin beta 1 Homo sapiens 90-102 33360300-11 2021 MiR-506-3p overexpression decreased the level of beta-catenin, and the sensitivity to olaparib and cisplatin mediated by miR-506-3p was partially reversed by regulating beta-catenin expression in ovarian cancer. Cisplatin 99-108 catenin beta 1 Homo sapiens 49-61 33360300-11 2021 MiR-506-3p overexpression decreased the level of beta-catenin, and the sensitivity to olaparib and cisplatin mediated by miR-506-3p was partially reversed by regulating beta-catenin expression in ovarian cancer. Cisplatin 99-108 catenin beta 1 Homo sapiens 169-181 33360300-12 2021 Our results suggest that miR-506-3p increases response to PARP inhibitors and cisplatin in serous ovarian cancer by targeting EZH2/beta-catenin signal pathway, which opens the possibility of using miR-506-3p overexpression as a potential therapeutic for ovarian cancer. Cisplatin 78-87 catenin beta 1 Homo sapiens 131-143 33506897-1 2021 OBJECTIVE: To explore the effect and mechanism of miR-217 in cisplatin resistance, as well as invasion and metastasis of ovarian cancer by inhibiting the expression of Cullin 4B (CUL4B) and the activation of Wnt/beta-catenin signaling pathway. Cisplatin 61-70 catenin beta 1 Homo sapiens 212-224 33506897-15 2021 MiR-217 can silence the expression of this gene, and inhibit the activation of Wnt/beta-catenin signaling pathway to enhance the cisplatin sensitivity and reverse drug resistance, inhibit cell invasion and migration, and promote cell apoptosis. Cisplatin 129-138 catenin beta 1 Homo sapiens 83-95 32472335-11 2020 Knockdown of circUBAP2 inhibited the cisplatin resistance, silenced Wnt/beta-catenin signaling pathway, hindered cell proliferation, migration and invasion, and promoted apoptosis in cisplatin-resistant OS cells, all of which could be reversed by overexpression of SEMA6D. Cisplatin 183-192 catenin beta 1 Homo sapiens 72-84 32835657-7 2020 Immunofluorescence analysis showed that ATAD2 overexpression reversed the miR-302-induced downregulation of nuclear beta-catenin in cisplatin resistant cells. Cisplatin 132-141 catenin beta 1 Homo sapiens 116-128 32977620-7 2020 In conclusion, the present study suggests that cisplatin-based adjuvant chemotherapy needs to be carefully applied to early stage NSCLC patients with overexpressed beta-catenin in combination with reduced NME1 expression. Cisplatin 47-56 catenin beta 1 Homo sapiens 164-176 33216839-0 2020 Evidence for functional and regulatory cross-talk between Wnt/beta-catenin signalling and Mre11-Rad50-Nbs1 complex in the repair of cisplatin-induced DNA cross-links. Cisplatin 132-141 catenin beta 1 Homo sapiens 62-74 33216839-6 2020 Consistently, the staining pattern of gammaH2AX-foci is significantly reduced in the cells exposed simultaneously to cisplatin and FH535; and (5) inhibition of Wnt/beta-catenin signalling impedes cisplatin-induced phosphorylation of Chk1, abrogates the G2/M phase arrest and impairs recombination-based DNA repair. Cisplatin 117-126 catenin beta 1 Homo sapiens 164-176 33216839-6 2020 Consistently, the staining pattern of gammaH2AX-foci is significantly reduced in the cells exposed simultaneously to cisplatin and FH535; and (5) inhibition of Wnt/beta-catenin signalling impedes cisplatin-induced phosphorylation of Chk1, abrogates the G2/M phase arrest and impairs recombination-based DNA repair. Cisplatin 196-205 catenin beta 1 Homo sapiens 164-176 32905529-11 2020 The expression and activity of beta-catenin known to involve cisplatin resistance was also up-regulated in cisplatin-resistant cells, which was further induced by 17beta-estradiol treatment. Cisplatin 61-70 catenin beta 1 Homo sapiens 31-43 32905529-11 2020 The expression and activity of beta-catenin known to involve cisplatin resistance was also up-regulated in cisplatin-resistant cells, which was further induced by 17beta-estradiol treatment. Cisplatin 107-116 catenin beta 1 Homo sapiens 31-43 32186756-0 2020 Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following beta-catenin silencing. Cisplatin 11-20 catenin beta 1 Homo sapiens 99-111 32525527-0 2020 MicroRNA-448 targets SATB1 to reverse the cisplatin resistance in lung cancer via mediating Wnt/beta-catenin signaling pathway. Cisplatin 42-51 catenin beta 1 Homo sapiens 96-108 32186756-1 2020 Resistance to the chemotherapeutic drug cisplatin has been documented in various types of cancer, while the increased expression of beta-catenin has been observed in cisplatin-resistant ovarian cancer. Cisplatin 166-175 catenin beta 1 Homo sapiens 132-144 32186756-3 2020 The present study investigated the antitumor effect of cisplatin on the proliferation, invasion and apoptosis of breast cancer (BC) cells following beta-catenin silencing in BC, which is the most frequent type of malignancy among women. Cisplatin 55-64 catenin beta 1 Homo sapiens 148-160 32186756-11 2020 Following knockdown of beta-catenin expression, cisplatin treatment suppressed the viabilities, and the migratory and invasive capabilities of the T47D and MCF-7 cells, and induced extensive apoptosis. Cisplatin 48-57 catenin beta 1 Homo sapiens 23-35 32186756-12 2020 beta-catenin knockdown upregulated caspase-3/9 levels following cisplatin treatment and induced the apoptosis of T47D and MCF-7 cells. Cisplatin 64-73 catenin beta 1 Homo sapiens 0-12 32186756-13 2020 In conclusion, beta-catenin may be of value as a therapeutic target during cisplatin treatment in patients with BC treated with cisplatin. Cisplatin 75-84 catenin beta 1 Homo sapiens 15-27 32186756-13 2020 In conclusion, beta-catenin may be of value as a therapeutic target during cisplatin treatment in patients with BC treated with cisplatin. Cisplatin 128-137 catenin beta 1 Homo sapiens 15-27 32117718-0 2020 Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/beta-Catenin Pathway. Cisplatin 63-72 catenin beta 1 Homo sapiens 91-103 32521857-0 2020 Cinnamolide sesquiterpene lactone suppresses in vitro and in vivo cancer cell growth in cisplatin-resistant human cervical carcinoma cells by inducing mitochondrial mediated apoptosis, caspase activation, loss of MMP and targeting Akt/beta-Catenin signaling pathway. Cisplatin 88-97 catenin beta 1 Homo sapiens 235-247 32028241-7 2020 In conclusion, FAM83H-AS1 is related with the CDDP and 5-FU insensitivity of GC patients, silence of FAM83H-AS1 promotes chemosensitivity of GC through Wnt/beta-catenin signaling pathway. Cisplatin 46-50 catenin beta 1 Homo sapiens 156-168 32203052-0 2020 Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/beta-catenin signaling pathway. Cisplatin 44-53 catenin beta 1 Homo sapiens 92-104 32256108-0 2020 LncRNA-ATB Promotes Cisplatin Resistance in Lung Adenocarcinoma Cells by Targeting the miR-200a/beta-Catenin Pathway. Cisplatin 20-29 catenin beta 1 Homo sapiens 96-108 32256108-10 2020 Mechanistically, lncRNA-ATB increased expression of beta-catenin by directly binding to MicroRNA-200a (miR-200a), thereby promoting cell survival and cisplatin resistance. Cisplatin 150-159 catenin beta 1 Homo sapiens 52-64 32256108-12 2020 Conclusion: In summary, this study revealed that lncRNA-ATB is dramatically up-regulated in cisplatin-resistant LUAD cell lines, and that lncRNA-ATB facilitates cell survival by targeting the miR-200a/beta-catenin pathway in these cells. Cisplatin 92-101 catenin beta 1 Homo sapiens 201-213 32104224-1 2020 Development of cisplatin resistance in colorectal cancer is largely caused by dysregulation of signaling pathways, including the Wnt/beta-catenin signaling pathway, in cancer cells. Cisplatin 15-24 catenin beta 1 Homo sapiens 133-145 31775307-8 2019 Furthermore, nuclear beta-catenin and cancer stem cell-related markers were upregulated in the cisplatin-resistant subpopulation of CL1-0 cells. Cisplatin 95-104 catenin beta 1 Homo sapiens 21-33 32038705-15 2019 Conclusions: In the OSCC cisplatin-resistant cell lines, NOTCH1, JUN, CTNNB1, CEBPA, and ETS1 were found as the hub genes involved in regulating the cisplatin resistance of OSCC. Cisplatin 25-34 catenin beta 1 Homo sapiens 70-76 32038705-15 2019 Conclusions: In the OSCC cisplatin-resistant cell lines, NOTCH1, JUN, CTNNB1, CEBPA, and ETS1 were found as the hub genes involved in regulating the cisplatin resistance of OSCC. Cisplatin 149-158 catenin beta 1 Homo sapiens 70-76 31878245-11 2019 In vivo, treatment with OV alone or in combination with CDDP significantly reduced the tumor sphere-forming ability and decreased EV cargos containing mTOR, PI3K, STAT3, beta-catenin, and miR-21-5p. Cisplatin 56-60 catenin beta 1 Homo sapiens 170-182 31609766-5 2019 SIN and cisplatin further decreased the Bcl-2, procaspase-3, and beta-catenin, but increased Bax, cleaved dcaspase 3, MMP9, and MMP2 in combined group than in either alone group. Cisplatin 8-17 catenin beta 1 Homo sapiens 65-77 31807029-0 2019 circ_0003418 Inhibits Tumorigenesis And Cisplatin Chemoresistance Through Wnt/beta-Catenin Pathway In Hepatocellular Carcinoma. Cisplatin 40-49 catenin beta 1 Homo sapiens 78-90 31807029-12 2019 The effect of circ-0003418 on sensitivity of HCC cells to cisplatin was reversed after inhibition of Wnt/beta-catenin pathway. Cisplatin 58-67 catenin beta 1 Homo sapiens 105-117 31882431-8 2019 Meanwhile, cisplatin chemosensitivity was enhanced by PDRG1 knockdown, via the suppression of cyclinD1 and beta-catenin expression within esophageal cancer cells. Cisplatin 11-20 catenin beta 1 Homo sapiens 107-119 31579066-0 2019 MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/beta-catenin signaling pathway. Cisplatin 14-23 catenin beta 1 Homo sapiens 125-137 31288529-0 2019 Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/beta-catenin pathway. Cisplatin 41-50 catenin beta 1 Homo sapiens 121-133 31452741-11 2019 Finally, the present study demonstrated that cisplatin combined with paclitaxel induced apoptosis and decreased the tumor markers in NPC cells through the Wnt/beta-catenin signaling pathway. Cisplatin 45-54 catenin beta 1 Homo sapiens 159-171 31579410-12 2019 These results suggested that inhibiting Wnt/beta-catenin signaling with CX4945, which attenuates levels of drug-resistance-associated proteins and induces apoptosis, might reverse cisplatin resistance in NSCLC. Cisplatin 180-189 catenin beta 1 Homo sapiens 44-56 31413820-0 2019 Correction: PARP-1 inhibitor modulate beta-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Cisplatin 72-81 catenin beta 1 Homo sapiens 38-50 31933859-3 2019 In the present study, we observed that the RNA level of NEAT1.1, one RNA variant of NEAT1, was reduced in cisplatin-sensitive T24 cells compared to cisplatin-resistant T24 (T24R) cells after both treated with cisplatin modulated through Wnt/beta-catenin signaling pathway using RNA-seq. Cisplatin 106-115 catenin beta 1 Homo sapiens 241-253 31303961-0 2019 PARP-1 inhibitor modulate beta-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Cisplatin 60-69 catenin beta 1 Homo sapiens 26-38 31303961-10 2019 In conclusion, PARP-1 inhibition might augment cisplatin cytotoxicity in cervical cancer cells by modulating beta-catenin signaling pathway. Cisplatin 47-56 catenin beta 1 Homo sapiens 109-121 31171023-0 2019 Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3beta/beta-catenin signaling pathway. Cisplatin 42-51 catenin beta 1 Homo sapiens 141-153 30844312-7 2019 ZNRF3, a ubiquitin ligase known to be a target and negative feedback regulator of Wnt-beta-catenin signaling, enhances cisplatin resistance in normal and melanoma cells independently of beta-catenin. Cisplatin 119-128 catenin beta 1 Homo sapiens 86-98 30809864-0 2019 Knockdown of the long noncoding RNA HOTTIP inhibits cell proliferation and enhances cell sensitivity to cisplatin by suppressing the Wnt/beta-catenin pathway in prostate cancer. Cisplatin 104-113 catenin beta 1 Homo sapiens 137-149 30809864-10 2019 Furthermore, the qRT-PCR, Western blotting, TOP/FOP assays, MTT assay, and flow cytometry revealed that Wnt/beta-catenin signaling was related to the regulation of HOTTIP in cell proliferation, cell cycle arrest, and chemoresistance to cisplatin in PCa. Cisplatin 236-245 catenin beta 1 Homo sapiens 108-120 30583038-9 2019 The upregulation of beta-catenin in the Wnt signaling pathway mediated proliferation, migration, invasion, and sensitivity to radiation and cisplatin treatment in bladder cancer cells. Cisplatin 140-149 catenin beta 1 Homo sapiens 20-32 30641908-7 2019 The participation of these processes in the increase of resistance to cisplatin was confirmed by silencing TP63 expression or by inhibition of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) activity in the IL-1beta/IL-1RI/beta-catenin signaling pathway. Cisplatin 70-79 catenin beta 1 Homo sapiens 235-247 30344736-0 2018 Expression of circ_001569 is upregulated in osteosarcoma and promotes cell proliferation and cisplatin resistance by activating the Wnt/beta-catenin signaling pathway. Cisplatin 93-102 catenin beta 1 Homo sapiens 136-148 30344736-6 2018 Moreover, upregulation of circ_001569 significantly promoted osteosarcoma cell resistance to cisplatin by activating Wnt/beta-catenin signaling pathway. Cisplatin 93-102 catenin beta 1 Homo sapiens 121-133 31949568-0 2018 Inhibition of WNT7A-beta-catenin signaling pathway sensitizes oral squamous cell carcinoma to cisplatin. Cisplatin 94-103 catenin beta 1 Homo sapiens 20-32 31949568-7 2018 Moreover, our results revealed that nuclear beta-catenin was dramatically reduced and cleaved caspase-3 and cleaved PARP were dramatically induced when WNT7A was knocked down in cisplatin treated KB cells. Cisplatin 178-187 catenin beta 1 Homo sapiens 44-56 31949568-10 2018 Our results revealed that inhibition of WNT7A-beta-catenin signaling sensitizes OSCC to cisplatin, which has provided insights into the molecular diagnosis and treatment of OSCC. Cisplatin 88-97 catenin beta 1 Homo sapiens 46-58 29699939-7 2018 High CILA1 expression levels and low levels of phosphorylated beta-catenin were closely associated with cisplatin resistance and advanced disease stage, and were predictors of poor prognosis in TSCC patients. Cisplatin 104-113 catenin beta 1 Homo sapiens 62-74 30015866-10 2018 In addition, the change in pERK1/2 and beta-catenin expression demonstrated that the mechanism of GOLPH3 overexpression involved in cisplatin resistance was associated with activation of the mitogen-activated protein kinase/ERK and Wnt/beta-catenin signaling pathways in HT29 cells. Cisplatin 132-141 catenin beta 1 Homo sapiens 39-51 30015866-10 2018 In addition, the change in pERK1/2 and beta-catenin expression demonstrated that the mechanism of GOLPH3 overexpression involved in cisplatin resistance was associated with activation of the mitogen-activated protein kinase/ERK and Wnt/beta-catenin signaling pathways in HT29 cells. Cisplatin 132-141 catenin beta 1 Homo sapiens 236-248 29071717-6 2018 The Wnt/beta-catenin pathway mediated the cancer stem-like properties in cisplatin-resistant TSCC cells. Cisplatin 73-82 catenin beta 1 Homo sapiens 8-20 29536130-0 2018 Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/beta-catenin/Endothelin-1 axis via activating B cell translocation gene 1. Cisplatin 0-9 catenin beta 1 Homo sapiens 124-136 29653464-0 2018 MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/beta-catenin pathway. Cisplatin 51-60 catenin beta 1 Homo sapiens 100-112 29243047-0 2018 Role of beta-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma. Cisplatin 24-33 catenin beta 1 Homo sapiens 8-20 29243047-8 2018 In addition, we found that LiCl-mediated up-regulation of beta-catenin in HNSCC-derived cells led to cisplatin resistance, evasion of apoptosis, enhanced DNA repair and enhanced migration. Cisplatin 101-110 catenin beta 1 Homo sapiens 58-70 28639895-0 2017 Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/beta-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. Cisplatin 42-51 catenin beta 1 Homo sapiens 71-83 29080815-0 2018 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/beta-catenin signaling pathways by up-regulating miR-34a. Cisplatin 49-58 catenin beta 1 Homo sapiens 134-146 29098029-7 2017 The results revealed that 5F and cisplatin synergistically induced apoptosis and inhibited cell growth, arrested cell cycles in the G0/G1 phase, downregulated beta-catenin, c-Myc and cyclin D1, and upregulated GSK-3beta. Cisplatin 33-42 catenin beta 1 Homo sapiens 159-171 28583847-0 2017 TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/beta-catenin signaling pathway and promoting the epithelial mesenchymal transition. Cisplatin 17-26 catenin beta 1 Homo sapiens 88-100 28639895-13 2017 Thus, our data suggested that upregulation of miR-199a/b in ALDHA1+ colorectal cancer stem cells contributed to cisplatin resistance via Wnt/beta-catenin-ABCG2 signaling, which sheds new light on understanding the mechanism of cisplatin resistance in colorectal cancer stem cells and facilitates the development of potential therapeutics against colorectal cancer. Cisplatin 112-121 catenin beta 1 Homo sapiens 141-153 28053596-8 2017 RESULTS: MDR1, MRP1, BCRP and Trkb, E-cadherin, beta-catenin were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased beta-catenin level was found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 149-158 catenin beta 1 Homo sapiens 48-60 28259951-4 2017 The present study aimed to explore the effects of Wnt/beta-catenin and Sox2 signaling on the chemoresistance of cisplatin-resistant lung cancer cells by assessing the effects of Sox2 on Wnt/beta-catenin signaling activity, cell migration, invasion and clonogenicity, and susceptibility to cisplatin in lung adenocarcinoma A549 cells and cisplatin-resistant A549/DDP cells. Cisplatin 112-121 catenin beta 1 Homo sapiens 54-66 28232512-6 2017 Furthermore, it was found that the cisplatin resistance acquired by Wnt/beta-catenin signalling activation depended on increased expression of Fra1. Cisplatin 35-44 catenin beta 1 Homo sapiens 72-84 28340578-12 2017 In contrast, cisplatin, the frequently used adjuvant chemotherapeutic agent, activated beta-catenin dependent signaling that lead to up-regulation of both ABCB1 and ABCG2 transporter expression and activity. Cisplatin 13-22 catenin beta 1 Homo sapiens 87-99 28386346-7 2017 Inhibiting eIF4E via siRNA knockdown or Wnt/beta-catenin using the Wnt inhibitor pyrvinium effectively enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in cervical cancer cells both in vitro and in vivo. Cisplatin 164-173 catenin beta 1 Homo sapiens 44-56 27831944-13 2017 Taken together, our findings suggested that RAGE blockade+cisplatin improved chemotherapeutic effects by reducing autophagy and regulating Wnt/beta-catenin to suppress the progression of TSCC. Cisplatin 58-67 catenin beta 1 Homo sapiens 143-155 28070043-8 2016 beta-catenin expression in SKOV3 /DDP cells with 2 or 6 mumol/L MSA plus cisplatin was higher than that in the cisplatin alone group (P<0.05). Cisplatin 73-82 catenin beta 1 Homo sapiens 0-12 29237155-0 2017 Paracrine Activation of the Wnt/beta-Catenin Pathway by Bone Marrow Stem Cell Attenuates Cisplatin-Induced Kidney Injury. Cisplatin 89-98 catenin beta 1 Homo sapiens 32-44 29237155-17 2017 CONCLUSION: The activation of the wnt/beta-catenin pathway by CM protects against cisplatin-induced kidney injury, resulting in reduced apoptosis and intracellular ROS levels. Cisplatin 82-91 catenin beta 1 Homo sapiens 38-50 28070043-8 2016 beta-catenin expression in SKOV3 /DDP cells with 2 or 6 mumol/L MSA plus cisplatin was higher than that in the cisplatin alone group (P<0.05). Cisplatin 111-120 catenin beta 1 Homo sapiens 0-12 28070043-9 2016 : Conclusion: MSA can reverse cisplatin resistance on SKOV3 / DDP cells, which may be related to the decrease in beta-catenin expression. Cisplatin 31-40 catenin beta 1 Homo sapiens 114-126 28101169-6 2016 Moreover, following treatment with 20 microM cisplatin, reduced expression of beta-catenin and JNK (P<0.05 and P<0.01 respectively), and increased expression of CaMKII (P<0.01), was observed in SKOV3 and SKOV3/DPP cell lines. Cisplatin 45-54 catenin beta 1 Homo sapiens 78-98 28101169-7 2016 Furthermore, inhibition of beta-catenin signaling by XAV-939 effectively reversed cisplatin chemoresistance in SKOV3/DDP cells. Cisplatin 82-91 catenin beta 1 Homo sapiens 27-39 28101169-9 2016 In conclusion, abnormal activation of Wnt/beta-catenin and Wnt/JNK signaling pathways in ovarian cancer cells promotes cisplatin resistance, while the Wnt/Ca2+ signaling pathway reduces cisplatin resistance. Cisplatin 119-128 catenin beta 1 Homo sapiens 42-54 27713506-3 2016 We provide evidence that PAK1 confers cisplatin resistance by increasing beta-catenin expression through ERK/GSK3beta signaling. Cisplatin 38-47 catenin beta 1 Homo sapiens 73-85 27895723-5 2016 The present study also demonstrated that cisplatin substantially inhibited beta-catenin, causing a marked downregulation of survivin and B-cell lymphoma (Bcl)-2. Cisplatin 41-50 catenin beta 1 Homo sapiens 75-87 27713506-4 2016 The increased beta-catenin expression promotes sphere cell formation and expression of stemness markers and this beta-catenin-induced stemness is responsible for PAK1-mediated cisplatin resistance. Cisplatin 176-185 catenin beta 1 Homo sapiens 14-26 27713506-4 2016 The increased beta-catenin expression promotes sphere cell formation and expression of stemness markers and this beta-catenin-induced stemness is responsible for PAK1-mediated cisplatin resistance. Cisplatin 176-185 catenin beta 1 Homo sapiens 113-125 27713506-7 2016 Patients with high-PAK1, high-pERK, and high-nuclear beta-catenin tumors more frequently showed an unfavorable response to cisplatin-based chemotherapy when compared to their counterparts. Cisplatin 123-132 catenin beta 1 Homo sapiens 53-65 27713506-9 2016 In conclusion, PAK1 confers cisplatin resistance in NSCLC via beta-catenin-mediated stemness. Cisplatin 28-37 catenin beta 1 Homo sapiens 62-74 27432651-0 2016 Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/beta-catenin signaling. Cisplatin 40-49 catenin beta 1 Homo sapiens 106-118 27432651-9 2016 Taken together, these results suggested that inhibition of DVL2 can sensitize cisplatin-resistant lung cancer cells through down-regulating Wnt/beta-catenin signaling and inhibiting BCRP, MRP4, and Survivin expression. Cisplatin 78-87 catenin beta 1 Homo sapiens 144-156 26540910-0 2015 [The study of siRNA interference after laryngeal cancer Hep-2 cells to cisplatin sensitivity of beta-catenin gene expression]. Cisplatin 71-80 catenin beta 1 Homo sapiens 96-108 26860078-0 2016 beta-Catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl. Cisplatin 41-50 catenin beta 1 Homo sapiens 0-12 26860078-1 2016 The Wnt/beta-catenin signaling pathway has been reported to regulate cisplatin resistance in several types of cancer cell. Cisplatin 69-78 catenin beta 1 Homo sapiens 8-20 26860078-2 2016 The present study aimed to investigate the role and underlying mechanism of Wnt/beta-catenin signaling in cisplatin resistance of lung adenocarcinoma cells. Cisplatin 106-115 catenin beta 1 Homo sapiens 80-92 26860078-12 2016 Notably, silencing of beta-catenin with siRNA decreased the mRNA and protein expression of Bcl-xl, and sensitized A549/WT cells to cisplatin (P<0.01). Cisplatin 131-140 catenin beta 1 Homo sapiens 22-34 26860078-13 2016 The findings of the current study suggest that upregulation of beta-catenin signaling may contribute to cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl. Cisplatin 104-113 catenin beta 1 Homo sapiens 63-75 26860078-14 2016 Therefore, molecular targeting of Wnt/beta-catenin signaling may sensitize lung cancer cells to cisplatin. Cisplatin 96-105 catenin beta 1 Homo sapiens 38-50 26522223-5 2015 In this study, we examined the expression of the Wnt/beta-catenin signaling components in the paired cisplatin-sensitive (A2780s) and cisplatin-resistant (A2780cp) EOC cell lines. Cisplatin 101-110 catenin beta 1 Homo sapiens 53-65 26522223-5 2015 In this study, we examined the expression of the Wnt/beta-catenin signaling components in the paired cisplatin-sensitive (A2780s) and cisplatin-resistant (A2780cp) EOC cell lines. Cisplatin 134-143 catenin beta 1 Homo sapiens 53-65 26125441-8 2015 Here we show that Wnt/beta-catenin signaling is activated in ovarian CICs, and targeted inhibition of beta-catenin potently sensitized cells to cisplatin and decreased CIC tumor sphere formation. Cisplatin 144-153 catenin beta 1 Homo sapiens 102-114 26125441-9 2015 Furthermore, the Wnt/beta-catenin specific inhibitor iCG-001 potently sensitized cells to cisplatin and decreased stem-cell frequency in platinum resistant cells. Cisplatin 90-99 catenin beta 1 Homo sapiens 21-33 26059239-0 2015 Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway. Cisplatin 32-41 catenin beta 1 Homo sapiens 104-116 27445486-3 2016 We previously found that lncRNA AK126698 suppresses cisplatin resistance in A549 cells through the Wnt/beta-catenin signaling pathway. Cisplatin 52-61 catenin beta 1 Homo sapiens 103-115 27347346-8 2016 In vitro, HOTTIP induced cellular resistance to cisplatin by activating the Wnt/beta-catenin pathway, which could be reversed by treatment with the Wnt/beta-catenin inhibitor. Cisplatin 48-57 catenin beta 1 Homo sapiens 80-92 27347346-8 2016 In vitro, HOTTIP induced cellular resistance to cisplatin by activating the Wnt/beta-catenin pathway, which could be reversed by treatment with the Wnt/beta-catenin inhibitor. Cisplatin 48-57 catenin beta 1 Homo sapiens 152-164 26820938-12 2016 Taken together, these data suggest that Pin1 contributes to cisplatin resistance, partly by up-regulating FoxM1 and Wnt/beta-catenin signaling pathway involved in cervical cancer. Cisplatin 60-69 catenin beta 1 Homo sapiens 120-132 26341496-7 2016 In vitro and in vivo, HOTAIR induced cellular resistance to cisplatin by activating the wnt/beta-catenin pathway, which could be reversed by pre-treatment with the wnt/beta-catenin inhibitor, XAV939. Cisplatin 60-69 catenin beta 1 Homo sapiens 92-104 26341496-7 2016 In vitro and in vivo, HOTAIR induced cellular resistance to cisplatin by activating the wnt/beta-catenin pathway, which could be reversed by pre-treatment with the wnt/beta-catenin inhibitor, XAV939. Cisplatin 60-69 catenin beta 1 Homo sapiens 168-180 27529071-0 2016 Overexpression of beta-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma. Cisplatin 39-48 catenin beta 1 Homo sapiens 18-30 27529071-2 2016 However, little is known about the relationship between abnormal expression of beta-catenin and cisplatin chemotherapy in oral squamous cell carcinoma (OSCC). Cisplatin 96-105 catenin beta 1 Homo sapiens 79-91 27529071-3 2016 The present study aimed to investigate the effect of beta-catenin on OSCC cisplatin resistance and evaluated the drug susceptibility of stable cell lines with beta-catenin knockin and knockdown. Cisplatin 74-83 catenin beta 1 Homo sapiens 53-65 27529071-4 2016 In this study, we found that higher expression level of beta-catenin can be observed in CDDP-treated cell lines as compared with the control group. Cisplatin 88-92 catenin beta 1 Homo sapiens 56-68 27529071-5 2016 Furthermore, the expression levels of beta-catenin increased in both a concentration- and time-dependent manner with the cisplatin treatment. Cisplatin 121-130 catenin beta 1 Homo sapiens 38-50 27529071-8 2016 Our findings indicated that overexpression of beta-catenin promoted cisplatin resistance in OSCC in vitro and in vivo. Cisplatin 68-77 catenin beta 1 Homo sapiens 46-58 27529071-10 2016 Our findings indicate that the Wnt/beta-catenin signaling pathway may play important roles in cisplatin resistance in OSCC. Cisplatin 94-103 catenin beta 1 Homo sapiens 35-47 26540910-1 2015 OBJECTIVE: To investigate the changes of laryngeal cancer Hep-2 cells to cisplatin chemosensitivity after the interference of siRNA of beta-catenin gene expression. Cisplatin 73-82 catenin beta 1 Homo sapiens 135-147 26540910-11 2015 The IC50 calculation software showed that IC50 of cisplatin on beta-catenin-siRNA IC50 interference group is (5.81 +- 0.46)mug/ml, the blank control group is (10.10 +- 1.01) mug/ml, the difference between the two groups has statistical signifi- cance (P < 0.01). Cisplatin 50-59 catenin beta 1 Homo sapiens 63-75 26540910-13 2015 CONCLUSION: To interfere the expression of beta-catenin can effectively enhance the sensitivity of laryngeal cancer cells to chemotherapeutic drugs cisplatin. Cisplatin 148-157 catenin beta 1 Homo sapiens 43-55 25573172-0 2015 Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/beta-catenin pathway. Cisplatin 39-48 catenin beta 1 Homo sapiens 97-109 25760455-6 2015 Compared to the parental cells, cisplatin-resistant NSCLC cells showed increased beta-catenin transcriptional activity. Cisplatin 32-41 catenin beta 1 Homo sapiens 81-93 25897700-0 2015 Therapeutic targeting of CBP/beta-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Cisplatin 178-187 catenin beta 1 Homo sapiens 29-41 24560772-0 2014 Activation of beta-catenin by inhibitors of glycogen synthase kinase-3 ameliorates cisplatin-induced cytotoxicity and pro-inflammatory cytokine expression in HEI-OC1 cells. Cisplatin 83-92 catenin beta 1 Homo sapiens 14-26 25131138-3 2014 beta-Catenin and c-Myc protein expression following cisplatin treatment were determined using western blotting and immunofluorescence. Cisplatin 52-61 catenin beta 1 Homo sapiens 0-12 25131138-6 2014 Endogenous beta-catenin and c-Myc expression in A549/DDP cells were higher than that in A549 cells, and were upregulated in A549/DDP cells (p < 0.05) and downregulated in A549 cells after 48 h cisplatin treatment (p < 0.05). Cisplatin 196-205 catenin beta 1 Homo sapiens 11-23 25131138-11 2014 C-myc, the downstream target gene of beta-catenin, plays an important role in regulating cisplatin resistance in A549/DDP cells. Cisplatin 89-98 catenin beta 1 Homo sapiens 37-49 24665856-11 2014 The results revealed that use of quadruplicate gemcitabine+cisplatin+DAC+TSA combination led to a reduced inhibition of canonical Wnt/beta-catenin pathway and reduced cell proliferation. Cisplatin 59-68 catenin beta 1 Homo sapiens 134-146 25658419-7 2015 beta-catenin-knockdown cells were more sensitive to chemotherapeutic agents doxorubicin and cisplatin. Cisplatin 92-101 catenin beta 1 Homo sapiens 0-12 24560772-8 2014 Our data suggest that the GSK-3/beta-catenin pathway may play a central role in cisplatin-mediated cytotoxicity in HEI-OC1 cells and hair cells of OCs in vitro. Cisplatin 80-89 catenin beta 1 Homo sapiens 32-44 24333218-0 2014 Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway. Cisplatin 99-108 catenin beta 1 Homo sapiens 149-161 23280703-0 2014 TWIST interacts with beta-catenin signaling on osteosarcoma cell survival against cisplatin. Cisplatin 82-91 catenin beta 1 Homo sapiens 21-33 23280703-6 2014 In conclusion, we demonstrate that TWIST decreases osteosarcoma cell survival against cisplatin by decreasing the soluble beta-catenin level through a PI3K-dependent manner. Cisplatin 86-95 catenin beta 1 Homo sapiens 122-134 23673211-0 2013 Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cisplatin 46-55 catenin beta 1 Homo sapiens 93-105 23756716-0 2013 Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/beta-catenin signaling. Cisplatin 54-63 catenin beta 1 Homo sapiens 87-99 23756716-4 2013 In this study, we found that nuclear accumulation of beta-catenin was higher in cisplatin-resistant Huh7 cells than in Huh7 cells, indicating that Wnt signaling was activated in cisplatin-resistant cells. Cisplatin 80-89 catenin beta 1 Homo sapiens 53-65 23756716-4 2013 In this study, we found that nuclear accumulation of beta-catenin was higher in cisplatin-resistant Huh7 cells than in Huh7 cells, indicating that Wnt signaling was activated in cisplatin-resistant cells. Cisplatin 178-187 catenin beta 1 Homo sapiens 53-65 23673211-10 2013 Analysis of downstream effectors of the Wnt/beta-catenin signaling pathway revealed upregulation of beta-catenin and survivin expression in A549/DDP cells treated with cisplatin as compared to untreated cells. Cisplatin 168-177 catenin beta 1 Homo sapiens 44-56 23673211-10 2013 Analysis of downstream effectors of the Wnt/beta-catenin signaling pathway revealed upregulation of beta-catenin and survivin expression in A549/DDP cells treated with cisplatin as compared to untreated cells. Cisplatin 168-177 catenin beta 1 Homo sapiens 100-112 23673211-11 2013 In A549 cells, cisplatin treatment decreased the expression of beta-catenin and survivin. Cisplatin 15-24 catenin beta 1 Homo sapiens 63-75 23673211-14 2013 In conclusion, activation of the Wnt/beta-catenin signaling pathway and upregulated survivin expression due to cytoplasmic GSK-3beta inhibition might lead to cisplatin resistance in NSCLC. Cisplatin 158-167 catenin beta 1 Homo sapiens 37-49 23673211-3 2013 The present study sought to examine the role of the Wnt/beta-catenin signaling pathway in cisplatin resistance by assessing the phosphorylation and subcellular distribution of GSK-3beta in a human lung adenocarcinoma cell line, A549, and its cisplatin-resistant subline, A549/DDP. Cisplatin 90-99 catenin beta 1 Homo sapiens 56-68 21687939-5 2011 Treatment with cisplatin plus TRAIL also inhibits Wnt-1 signaling and its downstream target, beta-catenin, phospho beta-catenin, cyclin D1, increased apoptosis, reduced proliferation and mammosphere formation. Cisplatin 15-24 catenin beta 1 Homo sapiens 93-105 22000491-4 2011 The results showed that beta-catenin shRNA expression resulted in decreased beta-catenin mRNA and protein expression in the transfected A2780 cells, inhibition of cellular proliferation, decreased capability of clonogenicity in the plating and the soft agar, and increased sensitivities to chemotherapy drugs vincristine, paclitaxel and cisplatin compared to untransfected cells. Cisplatin 337-346 catenin beta 1 Homo sapiens 24-36 23741487-12 2013 Knockdown lncRNA AK126698 not only greatly decreased NKD2 which can negatively regulate Wnt/beta-catenin signaling but also increased the accumulation and nuclear translocation of beta-catenin, and significantly depressed apoptosis rate induced by cisplatin in A549 cells. Cisplatin 248-257 catenin beta 1 Homo sapiens 92-104 23741487-12 2013 Knockdown lncRNA AK126698 not only greatly decreased NKD2 which can negatively regulate Wnt/beta-catenin signaling but also increased the accumulation and nuclear translocation of beta-catenin, and significantly depressed apoptosis rate induced by cisplatin in A549 cells. Cisplatin 248-257 catenin beta 1 Homo sapiens 180-192 23445611-5 2013 Inhibition of FZD8 by siRNA in CRL2335 cells in the presence of cisplatin plus TRAIL reduced beta-catenin and survivin levels and increased apoptosis compared with scrambled siRNA-treated cells. Cisplatin 64-73 catenin beta 1 Homo sapiens 93-105 21687939-5 2011 Treatment with cisplatin plus TRAIL also inhibits Wnt-1 signaling and its downstream target, beta-catenin, phospho beta-catenin, cyclin D1, increased apoptosis, reduced proliferation and mammosphere formation. Cisplatin 15-24 catenin beta 1 Homo sapiens 115-127 20074550-2 2010 In this study, we found that beta-catenin and OCT-4 was highly expressed in cisplatin (DDP) selected A549 cells. Cisplatin 76-85 catenin beta 1 Homo sapiens 29-41 18930135-7 2008 Furthermore, we found that cisplatin-induced downregulation of beta-catenin was partially suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231 cells, which indicated that knockdown of these two proteins may stabilize beta-catenin in cisplatin-induced apoptosis. Cisplatin 27-36 catenin beta 1 Homo sapiens 63-75 18930135-7 2008 Furthermore, we found that cisplatin-induced downregulation of beta-catenin was partially suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231 cells, which indicated that knockdown of these two proteins may stabilize beta-catenin in cisplatin-induced apoptosis. Cisplatin 27-36 catenin beta 1 Homo sapiens 224-236 18930135-7 2008 Furthermore, we found that cisplatin-induced downregulation of beta-catenin was partially suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231 cells, which indicated that knockdown of these two proteins may stabilize beta-catenin in cisplatin-induced apoptosis. Cisplatin 240-249 catenin beta 1 Homo sapiens 63-75 15381733-7 2004 Cisplatin also caused the early loss of cell-cell adhesions, which was associated with the altered localization of the adherens junction-associated protein beta-catenin in association with PKC-mediated phosphorylation of the actincapping protein adducin. Cisplatin 0-9 catenin beta 1 Homo sapiens 156-168 17234182-0 2007 Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance. Cisplatin 30-39 catenin beta 1 Homo sapiens 88-100 17234182-0 2007 Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance. Cisplatin 123-132 catenin beta 1 Homo sapiens 88-100 17234182-6 2007 Although cisplatin-resistant cells showed decreased plakoglobin mRNA, they retained equal expression of beta-catenin mRNA as parental cells. Cisplatin 9-18 catenin beta 1 Homo sapiens 104-116 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 67-76 catenin beta 1 Homo sapiens 13-25 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 67-76 catenin beta 1 Homo sapiens 145-157 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 67-76 catenin beta 1 Homo sapiens 145-157 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 93-102 catenin beta 1 Homo sapiens 13-25 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 93-102 catenin beta 1 Homo sapiens 145-157 17234182-8 2007 Furthermore, beta-catenin upregulation was closely associated with cisplatin exposure, since cisplatin-resistant HeLa subline also had increased beta-catenin, while vincristine-resistant HEp-2 subline did not upregulate beta-catenin. Cisplatin 93-102 catenin beta 1 Homo sapiens 145-157